Evaluation of the combination of ultrasound and elastometry
and serum biomarkers for the ultra-early diagnosis of hepatocellular carcinoma
Versandkostenfrei!
Versandfertig in 6-10 Tagen
47,99 €
inkl. MwSt.
PAYBACK Punkte
24 °P sammeln!
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It occurs in 75% to 80% of cases on cirrhosis. The annual incidence in France is 10,624 cases and it is responsible for 10,063 deaths per year. In 75% of cases, HCC is discovered incidentally. There is a relationship between the size of the tumour and the prognosis. Therefore, there is a need to improve screening and monitoring of patients with chronic liver disease and at high risk of HCC. The indications for biannual ultrasound monitoring are inconsistent, recommended in Europe for patients with cirrhosis (stage F4) or p...
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It occurs in 75% to 80% of cases on cirrhosis. The annual incidence in France is 10,624 cases and it is responsible for 10,063 deaths per year. In 75% of cases, HCC is discovered incidentally. There is a relationship between the size of the tumour and the prognosis. Therefore, there is a need to improve screening and monitoring of patients with chronic liver disease and at high risk of HCC. The indications for biannual ultrasound monitoring are inconsistent, recommended in Europe for patients with cirrhosis (stage F4) or pre-cirrhosis (stage F3), and in the United States only for patients with cirrhosis, with or without alpha-fetoprotein (AFP) testing. The aim of this study was to prospectively evaluate the effectiveness of HCC screening in day hospitals using FibroTest (AP-HP-Sorbonne University patent), combined with shear-wave elastography (SWE), B-mode morphological ultrasound and AFP testing.
Andere Kunden interessierten sich für
